Cytokine Release Syndrome
Researchers develop tool to predict CAR T-cell therapy-associated neurotoxicity
A new prognostic tool has been developed to help clinicians predict which patients may experience neurotoxic effects of chimeric antigen receptor T-cell therapy, according to a study published in JAMA Neurology.
NCCN patient guidelines provide ‘basic understanding’ of CAR T-cell therapy toxicities
The National Comprehensive Cancer Network published the latest in its series of guidelines intended to inform patients and their caregivers about adverse events associated with cancer therapies.
Navigating the journey to develop safer CARs
The development of chimeric antigen receptor T-cell therapy has revolutionized treatment for patients with advanced blood cancers.
Managing cytokine storm requires ‘important dialogue’ among rheumatologists, specialists
Rheumatologists are familiar with the enhanced inflammatory response seen in the most severe patients with COVID-19 and could play a key role in the fight against the virus, according to a presenter at the 2020 Interdisciplinary Autoimmune Summit.
Readmission rates reaffirm post-CAR-T infusion care policies
A 14% readmission rate after receipt of axicabtagene ciloleucel supports policies that require monitoring by a caregiver after discharge, according to results of a single-center study presented during the ASCO20 Virtual Scientific Program.
CAR-T, baseline risk factors confer elevated rate of major adverse CV events
Patients who were treated with chimeric antigen receptor T-cell therapy had increased risk for major adverse CV events, researchers found.
Off-the-shelf CAR T-cell therapy effective for advanced T-cell acute lymphoblastic leukemia
TruUCAR GC027 — a gene edited, investigational allogeneic chimeric antigen receptor T-cell therapy — showed efficacy for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia, according to preliminary results of a first-in-human phase 1 study presented at the virtual American Association for Cancer Research Annual Meeting.
Lisocabtagene maraleucel active, safe, ‘worth considering’ in outpatient setting for lymphoma subset
ORLANDO — Nearly three-quarters of a cohort of patients with relapsed or refractory large B-cell lymphoma responded to treatment with lisocabtagene maraleucel, according to results of the phase 1 multicenter TRANSCEND-NHL-001 trial presented at TCT | Transplantation & Cellular Therapy Meetings.
Researchers identify factors linked to impaired hematopoietic recovery after CAR T-cell therapy
ORLANDO — Pre-lymphodepletion platelet count, disease type, in vivo chimeric antigen receptor T-cell expansion and grade of cytokine release syndrome each appeared associated with impaired hematopoietic recovery following CD19-directed CAR T-cell therapy, according to results of a retrospective study presented at TCT | Transplantation & Cellular Therapy Meetings.
CAR-natural killer cell therapy induces response in non-Hodgkin lymphoma, CLL
Natural killer cells transduced with chimeric antigen receptors induced high response rates among patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and chronic lymphocytic leukemia, according to results of a phase 1/phase 2 study published in The New England Journal of Medicine.